Table 4.

ORs and 95% CIs for bladder cancer according to family history of selected cancers

Family-history cancer site	Cases (n = 1,158)	Controls (n = 1,244)	OR* (95% CI)
None	694	808	Reference (—)
All sites	464	436	1.32 (1.11-1.59)
Urinary bladder	16	9	2.34 (0.95-5.77)
Tobacco-associated sites^†	168	125	1.69 (1.28-2.23)
Non–tobacco-associated sites	300	288	1.18 (0.96-1.44)
Lip, oral cavity, and pharynx	11	10	1.34 (0.53-3.40)
Esophagus	16	8	2.73 (1.07-6.97)
Stomach	54	57	1.10 (0.72-1.68)
Intestine	38	48	0.93 (0.58-1.49)
Liver	40	46	1.04 (0.65-1.67)
Pancreas	14	10	1.43 (0.60-3.44)
Larynx	24	23	1.46 (0.77-2.79)
Lung	90	67	1.64 (1.14-2.36)
Bone	10	11	0.90 (0.36-2.26)
Female breast	57	43	1.50 (0.95-2.37)
Uterus, unspecified	18	19	1.41 (0.70-2.84)
Ovary	5	10	0.75 (0.25-2.31)
Prostate	43	29	2.15 (1.28-3.61)
Kidney	5	6	1.12 (0.30-4.09)
Brain	13	6	2.88 (1.00-8.27)
All lymphomas	3	2	1.83 (0.27-12.5)
Leukemia, unspecified	19	17	1.47 (0.71-3.02)

↵* After adjustment by unconditional logistic regression for age, gender, area, and smoking status of the subjects and average lifetime trihalomethane levels (μg/L).
↵† Include cancers of the oral cavity and pharynx, respiratory organs, esophagus, pancreas, urinary bladder, and kidney.